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Abstract: The transcription factor NF-kB plays a central role in the initiation of innate 
and adaptive immune responses via regulation of genes that encode various 
immunomodulatory proteins including cytokines and costimulatory molecules. NF-kB 
has been shown to become induced via a signal transduction pathway initiated by the 
activation of the Toll receptor. Here we seek to describe the function of a putative 
member of that pathway, the interleukin-1 receptor-associated kinase (IRAK). IRAK is a 
known member of a unique family of kinases referred to as serine/threonine innate 
immunity kinases (SIIK). Additionally, we report evidence explaining the function of the 
Toll receptor. In order to assess the function of IRAK we constructed a chimeric 
molecule consisting of the extracellular portion of the CD4 receptor and IRAK, which 
potentiates the ability of IRAK to induce NF-kB. Additionally, a kinase deficient form of 
this activated IRAK molecule was created to assess the role of phosphorylation in the 
function of IRAK. In order to test the role of the NH2-terminal death domain region in 
protein-protein interactions involved the NF-kB pathway we created death domain- 
deleted chimeric molecules as well. We then transfected human embryonic kidney 
epithelial cells containing a luciferase reporter gene driven by an NF-kB responsive 
promoter. Here we report that IRAK activates NF-kB and that activation does not 
absolutely require kinase activity. NF-kB activation by death domain-deleted molecules 
was potentiated by dimerization indicating a role for the death domain region in protein- 
protein interaction. CD4/IRAK-induced NF-kB activity was inhibited by a dominant 
negative version of known signal transducer TRAF6 indicating a downstream position of 
this protein. Additionally we report that Toll activation of NF-kB is potentiated by 
dimerization. Thus, we conclude that IRAK is a SIIK involved in the Toll/NF-kB 
pathway upstream of the TRAF6 protein. The function of IRAK in this pathway is not 
solely mediated by kinase activity. Additionally, we conclude that the Toll receptor may 
function in a dimer suggesting the putative ligand is likely generated by an endogenous 
process. 
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The mechanism by which an organism defends itself against infectious agents has 
occupied the thoughts of countless researchers over the last 200 years. Over that time it 
has become apparent that the human immune response is two-pronged. One facet is a 
specific response, known as an adaptive immune response, designed to protect against a 
particular pathogen. The other is innate immunity. By contrast, innate immunity has the 
potential to protect against a wide range of pathogens. Much research in the field of 
immunology today is directed toward elucidating the interplay between these two 
responses. 
1.1 Adaptive Immunity 
Adaptive immunity is dependent upon the recognition of specific pathogens. This 
is accomplished by the production of antibodies by activated B-lymphocytes. Antibodies 
are encoded by specialized regions of DNA which are capable of somatically 
recombining.’ This act of recombination allows B cells to elaborate antibodies adept at 
recognizing many pathogen-associated antigens with a relatively few number of genes. 
Nevertheless, the induction of an adaptive immune response requires the 
activation of other elements of the immune system. Upon initial infection with a 
microorganism, host cells specialized in the initiation of an immune response become 
activated. These cells are referred to as professional antigen presenting cells (APC) and 
consist of essentially three types of cells with somewhat differing functions: dendritic 




The initiation of specific immunity begins with the presentation of foreign antigen 
on the surface of APCs. This is accomplished with the help of glycoproteins encoded for 
by genes of the major histocompatabilty complex. Thus, the proteins are termed MHC 
proteins. Upon encountering a microorganism, APCs ingest the pathogen into lysosomal 
and endosomal compartments where foreign peptides are digested. The vesicles which 
contain these fragments then fuse with vesicles containing MHC class II proteins. The 
peptides then bind the MHC class II molecules in a specific manner at which point they 
are transported to the surface of the APC. 
It is at this point that naive T lymphocytes recognize the MHC/peptide molecule. 
This interaction occurs not at the primary site of infection but at peripheral lymphoid 
organs such as Peyer’s patches in the digestive tract and the tonsils. T cells possess 
receptors that are generated in much the same way antibodies are. Thus, each organism 
has the ability to produce a vast repertoire of T cell receptors (TCR) capable of 
recognizing an enormous variety of MHC/peptide complexes. Additionally, there exist a 
number of other families of molecules which mediate T cell/APC interaction. These 
include selectins, vascular addressins, integrins (specifically leukocyte function- 
associated antigen-1) and intercellular adhesion molecules (ICAMs) which contribute to 
homing and migration of lymphocytes as well as APC binding, thus ensuring that T cells 
reach their proper target cell."^’^ 
The process of priming, activating naive T cells into effector T cells, requires 
more than recognition by a somatically recombined TCR of its MHC/peptide ligand. In 
addition to the presentation of the CD4 molecule, which is required for T cell recognition 
of MHC class Il/peptide molecules on the surface of APCs, T cells must also recognize a 
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second signal from APCs. This signal, which has been termed costimulation, is mediated 
through the expression of glycoproteins in the B7 family. The receptor on the surface of 
T cells responsible for the recognition of this costimulatory ligand is CD28. Several 
experiments have shown that CD28 cross-linking is an essential feature of T cell 
activation and that the absence of such recognition, even in the presence of a specific 
MHC/TCR interaction will lead to a quiescent T cell state known as anergy.^’^’*’^ Anergic 
T cells are refractory to activation. 
Once the naive T cell binds both the MHC class Il/peptide and the costimulatory 
molecule on the surface of the APC, it becomes activated. At this point the T cell begins 
to elaborate a growth factor known as interleukin-2 (IL-2) which triggers clonal 
proliferation of T cells bearing the specific TCR of the activated clone. It is at this point 
when the CD4 T cell will further differentiate into a THl or TH2 cell. THl cells direct 
an inflammatory response by secreting macrophage-activating cytokines interferon- 
y (IFN-y), granulocyte-macrophage colony stimulating factor (GM-CSF) and tumor 
necrosis factor-P (TNF-P). TH2 cells trigger a humoral immune response by elaborating 
B-cell activating cjdokines IL-4, IL-5 and IL-6. Upon signaling with these cytokines, B- 
cells are activated to differentiate into specialized antibody-secreting cells. Additionally, 
the-predominance of a specific cytokine in the TH2 pathway is responsible for signaling a 
specific type of antibody response, e.g. IgG, IgE, etc. 
Note that this has been a rather cursory look at how the human organism develops 
specific effector T cells that can rapidly initiate an adaptive immune response upon 
further inoculation with a specific offending organism. The key event in this pathway, 
for our purposes, is the expression of the costimulatory molecule by the APC. While the 
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mechanism for the prevention of autoimmunity has been historically cited as the process 
of negative selection of autoreactive T cells in the thymus, there is evidence to support 
the notion that many T cells capable of recognizing self-peptides presented by MHC 
molecules reach the circulation. Additionally, under this hypothesis, there exists no 
mechanism to delete T cells bearing receptors capable of recognizing innocuous non-self 
peptides presented in the context of MHC. Thus, there must exist another mechanism for 
the prevention of autoimmunity and destructive hypersensitivity reactions, both of which 
are far less prevalent in the human population than that which would be predicted without 
such a mechanism in place. As we shall see, the presentation of costimulatory molecules 
provides that mechanism. Additionally, the method by which organisms induce 
costimulation provides a glimpse into the much sought-after link between adaptive and 
innate iimnunity. 
1.2 Innate Immunity 
In contrast to the highly specific nature of adaptive immunity, there exists a 
mechanism of host defense that acts in a more immediate and general fashion. This has 
been termed innate immunity. Host organisms encounter countless challenges from 
invading microorganisms in a constant manner. Yet, a disease state arising from 
infection occurs only occasionally. Most foreign invaders are destroyed within a short 
period of time by this system of iimate immunity. 
One important method of host defense is the activation of the complement 
pathway. Although there exist three pathways of complement activation, the endpoints 
are similar. The result of complement activation is three-pronged. The production of 
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peptides C3a, C4a, and C5a result in an inflammatory response and act as chemotactic 
agents for host phagocytic cells.Additionally, complement is responsible for the 
opsonization of pathogens. Because macrophages possess complement receptors, 
engulfment and destruction of opsonized microorganisms can occur. Lastly, the end 
result of the complement pathway is the production of a membrane attack complex 
consisting of the components C5b, C6, C7, C8 and C9.** This complex has the ability to 
create a pore in the membrane of attacking pathogens thus directly leading to their 
demise. 
While the endpoints of complement activation are quite similar there are, as I 
have stated before, three mechanisms for activating this pathway. One is the classical 
pathway. This pathway is activated via antibody-antigen interaction and thus can be 
classified as part of an adaptive immune response. The second method is the lectin 
pathway which is initiated by the cross-linking of the mannose binding protein to certain 
carbohydrate structures on microorganisms. The last pathway is the alternative pathway. 
The alternative pathway is initiated with direct interaction between an activated 
complement component and the surface of a pathogen. Both the lectin and alternative 
pathway share features consistent with innate immunity. 
In the alternative pathway of complement activation, spontaneously cleaved C3b 
binds to the surface of a microorganism where it attaches to factor B. Factor B is then 
cleaved to Bb by factor D. Through a series of events, the C3b/Bb complex acts as a C3 
convertase to initiate the complement cascade, which results in opsonization, the 
production of the potent inflammatory peptide C5a and the activation of terminal 
complement components. The possibility of alternative complement activation against 
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self is tightly regulated by the presence of complement control proteins CRl, H, MCP 
and DAF on the surface of host cells. These proteins disrupt the C3b/Bb complex 
preventing completion of the complement cascade.'^ 
The lectin pathway, however, initiates a cascade, which is very similar to that of 
the classical pathway. The key step is the production of one of a family of proteins 
referred to as collectins. An example of a collectin is mannose-binding protein (MBP) 
which can recognize mannose residues which tend to be more accessible on bacterial 
surfaces compared with those of vertebrates. MBP normally exists at low levels in the 
serum but is quickly upregulated with infection. MBP is structurally similar to the Clq 
protein, which is responsible for the initiation of the classical complement pathway. Like 
Clq, MBP can act as an opsonin or initiate the complement pathway which eventually 
results in the production of proinflammatory peptides or the activation of the membrane 
attack complex. As we shall see, MBP is known as an acute phase response protein 
(APR) whose elaboration is elegantly tied to innate immune mechanisms. 
Another important mechanism of innate immunity is the function of host 
macrophages. Macrophages act as the primary agent of innate immunity in three 
important ways. First, through the use of surface receptors they are able to recognize 
opsonized (Fc and complement receptors) pathogens or many microbial structures 
(mannose receptor, scavenger receptor, CD 14). This recognition leads to engulfment and 
destruction of microbes through the production of oxygen radicals. Secondly, the 
interaction between a macrophage and pathogen leads to the secretion of cytokines. 
These intercellular signals provide valuable chemotactic instruction to cells of the 
immune system as well as initiating an inflammatory response. Lastly, macrophages are 
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important in antigen presentation and costimulation which leads ultimately to the 
induction of an adaptive immune response. 
We have already seen how the presentation of costimulatory molecules is 
necessary for the initiation of an adaptive immune response. What is less obvious is the 
effect of cytokine secretion by activated macrophages on the initiation and potentiation of 
adaptive immunity. Of the myriad of mediators released by the macrophage in response 
to an invading organism perhaps the most important and best studied molecules are IL-1, 
IL-6, IL-8 and TNF-a. 
IL-1 is primarily a potentiator of the inflammatory response. By activating 
vascular epithelium at the cellular level, IL-1 increases the ability of effector cells to 
reach the nidus of infection. Additionally, IL-1 can activate lymphocytes and, by acting 
on the hypothalamus, increase the set point of basal body temperature resulting in fever. 
Importantly, IL-1 potentiates the transcription of IL-6. 
IL-6 is an important activator of antibody production. Thus, there is a direct link 
between innate and adaptive immunity via this molecule. In addition, IL-6 is chiefly 
responsible for inducing hepatocytes to produce the acute phase reactants.*^ We briefly 
visited the APRs before with MBP. Additional APRs include serum amyloid protein, the 
clotting protein fibrinogen, and C-reactive protein which, like MBP can bind to 
pathogens in a fashion similar to antibody and either cause opsonization or initiation of 
the complement cascade. The acute ph^lse reactants thus provide a challenged organism 
















IL-8 is sometimes referred to as a chemokine because its main function is to serve 
as a chemoattractant for various leukocytes. Thus, the mediators of the immune response 
are directed to the proper location. 
TNF-a is a potent molecule capable of initiating an increase in vascular 
permeability which allows for the extravasation of antibody, complement and effector 
cells. In this way it can be seen as a potentiator of the adaptive immune response. Taken 
to its extreme, the systemic action of TNF-a can cause septic shock and disseminated 
intravascular coagulation (DIC). 
The result of this barrage of cytokines is the inflammatory response. The site of 
infection is quickly made accessible to various components of both adaptive and innate 
immunity ranging from complement and antibody to APRs to effector cells. 
Additionally, systemic ramifications play a part in infection control. The elevation of 
host core temperature retards microbial growth patterns. Providing another link between 
innate and adaptive immunity, this initial induction of cytokines is responsible for 
systemic leukocytosis. The rapid influx of neutrophils is important for both adaptive and 
iimate immunity.*^ 
1.3 Pattern Recognition 
The mechanism by which triggers of innate immunity confer an adaptive immune 
response has been extensively studied in the past several years. Specifically, several 
questions have spurred an interest in the scientific community. How does the human 
immune system discriminate APCs presenting self and innocuous nonself antigen from 
those that present antigens belonging to infectious agents? How does the human immune 
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system compare to those of evolutionarily older organisms? Can we learn about the 
function of human immunity through the study of ancient systems of defense? Are there 
legitimate targets for improved manipulation of the human immune system in the fight 
against disease? 
It has been proposed that the immune system of vertebrates can delineate the 
origin of antigens and direct an appropriate immune response via the action of a non- 
clonal system of receptors. When these receptors bind their respective ligands, a signal 
transduction cascade leads to the expression of costimulatory molecules and the 
10 'JCi 91 
production of effector cytokines ’ ’ 
Although adaptive immunity occurs only in vertebrates, all multicellular 
organisms possess receptors whose function is host defense. The ligands for these 
receptors are molecular patterns that are uniquely microbial in origin. Termed pathogen 
associated molecular patterns (PAMPs) they are necessarily invariant in their expression. 
Without the ability to alter the structure of such molecules, which would result in 
deleterious implications for their survival, pathogens lack the ability to evade detection 
by this novel class of receptors, termed pattern recognition receptors (PRR). ’ ’ The 
activation of these receptors then becomes a means to alert the host organism that an 
infectious agent is present. Thus, there exists a mechanism for delineating self and 
innocuous nonself, which do not express PAMPs, fi-om infectious nonself, which 
necessarily does. 
Such a receptor has long been known to exist in the invertebrate Drosophila. 
Although the Toll receptor was originally discovered as a protein important in the 







have implicated it in host defense.^^’^^ Specifically, the activation of the Toll receptor 
induces the production of the potent antifungal peptide drosomycin.^^ Recently, the 
human homologue of the Toll protein was cloned.^^ This protein is remarkably similar to 
its counterpart in Drosophila in both structure and function. Both are type I 
transmembrane proteins with an extracellular leucine-rich region (LRR), a cytoplasmic 
domain homologous to that of the human interleukin-1 receptor (the Toll/IL-1 receptor 
domain or TIR). Additionally, both were shown to signal through the NF-kB pathway. 
Induction of the human Toll receptor was shown to induce the expression of NF-kB 
controlled genes IL-1, IL-6 and IL-8. Perhaps most intriguing was that cross-linking Toll 
induced the expression of the costimulatory molecule B7.1. Recent evidence now 
implicates the Toll receptor as the deficient protein in the TPS'* mouse, suggesting that 
7Q 
lipopolysaccharide (LPS) is involved in the activation of Toll. 
With the discovery of the Toll protein and its implications in the invertebrate and 
vertebrate immune responses, an important link has been established. We now have two 
organisms, separated by hundreds of millions of years of evolution, that possess a 
virtually identical mechanism of innate immunity. Additionally, it has been shown, 
through the induction of B7.1 by cross-linking human Toll, that vertebrates have evolved 
an adaptive immune response which elegantly interacts with the evolutionarily older 
innate immunity. This adaptive immune response critically depends upon the first step, 
the binding of the PRR with its associated PAMP. Without this event, there is no signal 
of a foreign invader and the effector cells of adaptive immunity are not marshaled. 







kB pathway has become the target of intense scrutiny. It is hoped that, through a greater 
understanding of this pathway, advances can be made in the treatment of human disease. 
1.4 The NF-kB Pathway 
NF-kB, a dimer consisting of members of the rel family of proteins, is a 
transcription factor that was first described in 1986 in reference to its ability to drive the 
transcription of the immunoglobulin kappa light chain genes in B cells.^^ Since that time, 
it has been found to drive the activation of several immunologically important genes 
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including cytokines, acute phase response proteins, and cell adhesion molecules. ’ ’ 
Among the myriad of NF-kB responsive genes are the APRs serum amyloid protein, 
angiotensinogen, C3 complement and complement factor B as well as the cytokines IL-1, 
IL-2, IL-6, IL-8, G-CSF, GM-CSF, TNF-a, TNF-P and interferon-p (IFN-P). 
Additionally, the costimulatory molecule B7.1 is inducible through NF-kB.^"^ Although 
NF-kB transcription has been shown to be induced by many proinfiammatory and 
immunomodulatory molecules including IL-1, LPS, CD30 and CD40 ligands, TNF, 
lymphotoxin-a and lymphotoxin-p 35,36,37,38,39,40 concentrating on the pathway 
as it pertains to the activation of the Toll receptor and its putative ligand. It should, 
however, be noted that the majority of the pathway is conserved or homologous between 
activating receptors. 
The activation of NF-kB is regulated by its cytoplasmic inhibitor, IkB. Under 
normal circumstances IkB binds NF-kB in a manner that prevents the presentation of its 
nuclear localization signal thus sequestering NF-kB in the cytoplasm.'^* When the NF- 
kB pathway becomes activated, IkB is phosphorylated, ubiquinated and degraded by the 
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proteasome leading to dissociation from in this manner the inhibitor is 
degraded and the newly released NF-kB can now translocate to the nucleus and activate 
transcription of its responsive genes. 
Recently, a kinase complex, termed the signalsome, consisting of the NF-kB- 
inducing kinase (NIK) and two IkB kinases (IKKa and IKKP) has been implicated in the 
phosphorylation of IkB.NIK is thought to be the protein responsible for 
binding upstream regulatory elements while the IKKs have been shown to phosphorylate 
IkB on specific serine residues. Thus there exists a directly upstream mechanism by 
which IkB is phosphorylated, leading to its degradation and the activation of NF-kB. 
NIK has been shown to interact with a family of proteins referred to as TNF- 
receptor associated factors (TRAF)'**’^^ placing this family of proteins directly upstream 
in the pathway. The TRAFs are signal transducing proteins characterized by a conserved 
carboxy-terminal TRAF-C domain, an a-helical TRAF-N domain and an amino-terminal 
RING finger.Recent evidence has implicated a member of the TRAF family involved 
in IL-1 and Toll-mediated NF-kB activation.^^ This novel protein is referred to as 
TRAF6. 
TRAF6, in turn, has been found to interact with a serine/threonine kinase referred 
to as IL-1 receptor-associated kinase (IRAK).^^ However, the study that reported the 
cloning of IRAK did not show direct NF-kB activation by this newly discovered 
protein.^^ Nevertheless, a striking homology to the ser/thr kinase Pelle in Drosophila and 
experiments showing a coprecipitation with TRAF6 in IL-1 treated cells^^ as well as 
experiments showing that an antibody to IL-IRI will coprecipitate with IRAK and not 
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TRAF6 in IL-1 treated cells^^ implies that IRAK is instrumental in recruiting TRAF6 to 
the IL-R complex. 
The final link in the pathway is the adapter molecule MyD88 which has been 
shown to interact with IRAK via homologous death domains.Additionally, MyD88 
contains a C-terminal TIR domain which has been shown to interact with the cytoplasmic 
domains of both the IL-1 receptor and Toll. Experimental evidence has shown NF-kB 
activation with overexpression of MyD88 as well as inhibition of Toll-activated NF-kB 
by a dominant negative version of the protein. Thus, MyD88 provides the most 
upstream link in the signal transduction pathway of the IL-IR/Toll family which 
ultimately results in the activation of NF-kB responsive genes. 
1.5 A Conserved Pathway 
Perhaps the most striking element of this pathway is how remarkably it has been 
conserved over evolutionary time. Similar pathways exist not only in invertebrates, but 
recent evidence points to a link to the host defense systems of plants as well, placing 
conserved elements of this pathway in organisms separated by one billion years of 
evolutionary history. This conservation is a testament to the elegance and efficiency of 
this pathway. 
1.5.1 Drosophila 
The response of Drosophila and other insects to infectious challenge is the rapid 
synthesis of antimicrobial peptides in the fat body and hemocytes of the orgamsm. The 
genes that encode these proteins contain regulatory regions with multiple binding sites for 
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transcription factors of the rel family.^*’^^ In fact, three members of this family. Dorsal, 
Dif and Relish, have been shown to become activated in response to infection.^^’^'^’^^ As 
members of the rel family, these transcription factors all share homology with NF-kB. 
Perhaps the signal transduction pathway of rel-related proteins in invertebrates is 
best understood in the case of the Drosophila Toll-Dorsal pathway. As stated before. 
Toll is a membrane-bound receptor that was first identified via its role in determining 
dorsal-ventral patterning in the Drosophila embryo.^^’^"* Later studies implicated it in the 
induction of the antifungal peptide drosomycin.^^ Elegant double-mutant analysis has 
elucidated the order of aetion of many of the proteins involved in the Toll-Dorsal 
signaling pathway.^"^ 
The ligand of the Drosophila Toll-Dorsal pathway is a molecule called Spatzle, 
which itself is the result of proteolytic cleavage. Upon binding and activation of Toll, 
two intracellular proteins become recruited and activated. Tube is thought to function as 
an adapter protein and, thus, appears to be a functional analog of MyD88 in the NF-kB 
pathway. Tube is responsible for the recruitment of the serine/threonine kinase Pelle, 
which shares remarkable homology with IRAK, to the receptor complex. Pelle, in turn, 
complexes wdth a recently cloned intermediary dTRAF which, as its names suggests, is 
the likely Drosophila homolog of TRAF6.^^ Through mechanisms which have not been 
completely described, the activation of dTRAF results in the phosphorylation of IkB 
homolog Cactus. This phosphorylation results in the rapid degradation of Cactus. 
Released from the inhibition of Cactus, Dorsal translocates to the nucleus where it effects 





Several reviews on plant host defense mechanisms have recently been published 
which show a remarkable conservation between components of the mammalian NF-kB 
and Drosophila Toll-Dorsal pathways and the products of plant resistance (R) genes.^^’^^ 
Conserved domains found include the TIR domain, the LRR domain and serine/threonine 
kinases homologous to IRAK and Pelle. Particularly striking is the tobacco N protein 
which contains not only a LRR domain homologous with the extracellular portion of the 
Toll receptor but also the TIR domain, which is present on the cytoplasmic portion of 
Toll. 
Of particular interest is a group of R genes bearing resemblance to the 
serine/threonine kinases IRAK and Pelle. Members of this group include the tomato 
proteins pto, pti, and fen. This has led to the classification of these homologous proteins 
in a group referred to as serine/threonine innate immunity kinases (SIIK). The 
remarkable homology that exists between these molecules and other components of this 
pathway is summarized in Figure 1. 
The conservation of major portions of host defense mechanisms across organisms 
separated by more than 1 billion years of evolution has great significance. Of perhaps 
greater interest is the conclusion that mammals have co-opted this ancient system of 
innate immunity as a trigger for antigen-specific adaptive immunity through the induction 
of costimulatory molecules.^^ 
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Ancient Host Defense Pathways 
Vertebrates inseas Plants 
Fig. 1 A schematic representing conserved elements of host defense. On the left, the vertebrate system 
signals through two distinct receptors, the IL-1 receptor and the Toll receptor, both of which posses a 
homologous Toll/IL-IR (TIR) domain. The adapter molecule MyD88 complexes with the receptor via its 
own TIR domain as well as with the serine/threonine innate immunity kinase (SIIK), II-1 receptor- 
associated kinase (IRAK) through homologous death domains (DD). IRAK then signals through TNF 
receptor-associated factor 6 (TRAF6) which, in turn activates a kinase complex consisting of NF-kB 
inducing kinase (NIK) and two IkB kinases (IKK). Thus IkB becomes phosphorylated, its degradation is 
signaled and the transcription factor NF-kB translocates to the nucleus where it activates genes important in 
host defense. The insect pathway, represented by the Drosophila Toll receptor is depicted in the middle. 
The adapter protein Tube performs a similar function as the mammalian MyD88. Similarly, Pelle is a SIIK 
with a function similar to that of IRAK. DTRAF is the Drosophila homologue of TRAF6 and was recently 
described. Cactus is the cytoplasmic inhibitor of the rel related proteins Dorsal, Dif, and Relish which can 
induce the transcription of host defense genes, specifically those that encode for antimicrobial peptides. 
The mechanisms of host defense in plants are less clear. Nevertheless, there exist proteins, products of 
plant resistance (R) genes that share extensive homology with components of vertebrate and invertebrate 
host defense. For example the tomato pto, pti, and fen genes encode SIIKs homologous to IRAK and Pelle. 
The tobacco N protein, the flax L6 protein and the arabidopsis RPP5 all contain leucine rich regions (LRR) 
and domains similar to the intracellular portion of Toll (TIR). However, contrasting the membrane-bound 
receptors of vertebrates and invertebrates, these proteins are expressed intracellularly. The Xa-21 rice 




IRAK is a 712-amino acid SIIK that was first reported in 1996.^^ The protein was 
first obtained by coimmunoprecipitation with the IL-RI from embryonic kidney epithelial 
cells (293 cells) that were stimulated with IL-1. Micropeptide sequencing, construction 
of PCR primers, amplification of a cDNA probe and screening of a teratocarcinoma 
cDNA library resulted in the cloning of the full-length gene. Sequence analysis revealed 
a putative kinase domain (residues 208-524) with 12 subdomains and 15 highly 
conserved amino acids suggestive of a protein kinase.This kinase domain shares 
extensive homology with the tomato kinase pto (30%)^* and Drosophila Pelle (32%). 
Additionally, IRAK and Pelle are 50% homologous in a region spanning kinase 
subdomains IV to VII. Note that this relatedness is significantly greater than that which 
exists between IRAK and its closest mammalian protein, human mixed-lineage kinase 
(25%). Also of interest is the amino-terminal death domain which shares weaker 
homology with the corresponding region in Pelle. It is this death domain that is required 
for the interaction between IRAK and MyD88.^* Fig. 2. 
Activation Loop 
364-388 
300 400 500 600 
_J_I_I_L 




Fig. 2 Schematic of the IL-1 receptor-associated kinase (IRAK). IRAK is a member of the family of 
serine/threonine innate immunity kinases (SIIK). Its key features are an amino-terminal death domain 
which shares homology with a similar region on the adapter molecule MyD88 as well as a kinase domain 
spanning residues 208-524. Of the several highly conserved kinase residues, our target for creation of a 
kinase deficient protein was the lysine at position 239, marked in red. 
The study that originally described IRAK also provides some clue as to its 
function. It was shown that IRAK/IL-IR interaction is IL-1 dependent and that IRAK 
( 
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becomes highly phosphorylated upon activation.^^ A more recent study has shown, by 
virtue of nonspecific kinase inhibition, that IRAK/IL-IRI complex formation is not 
dependent upon phosphorylation and that the phosphorylation of IRAK is likely a signal 
for its degradation by the proteasome, in a similar fashion to IkB7^ Nevertheless, there 
has been no successful attempt to induce a more than 3 fold increase in NF-kB activity 
through overexpression of IRAK. As such, it is difficult to describe the role of IRAK in 
NF-kB signal transduction. We postulate that in order for IRAK to activate NF-kB, it 
must first be recruited to the cell membrane. Here we report the construction of a NF- 
icB-activating form of IRAK and evidence that may help explain how it functions in vivo. 
2. Statement of Purpose 
The aim of this study is to establish the molecule IRAK as a participant in signal 
transduction of the To11/IL-1R/NF-kB pathway. Additionally, we seek to describe the 
organizational structure and interaction of other proteins involved in this cascade. 
3. Materials and Methods 
3.1 Constructs 
Reasoning that translocation to the cell membrane is required for activation of 
IRAK, a chimeric molecule containing the extracellular domain of CD4 fused to IRAK 
was created. Full length IRAK was obtained from E. Kopp. Full length CD4 was 
obtained from R. Medzhitov. The extracellular domain (residues 1-387) of CD4 was 
generated by PCR incorporating a downstream EcoRI site. This fragment was then 
subcloned into the vector pCINEO. IRAK (residues 8-712) was generated by PCR 
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incorporating an upstream EcoRI site. This fragment was then subcloned into the vector 
pCINEO. The IRAK fragment was then subcloned in-frame downstream of the CD4 
fragment in pCINEO utilizing the engineered EcoRI site. A kinase deficient mutant of 
IRAK was made using PCR based site-directed mutagenesis to change the lysine residue 
at position 239 to alanine resulting in the IRAK K239A mutant. (Fig. 2) A chimeric 
molecule incorporating the extracellular portion of CD4 was then constructed in a similar 
fashion as described previously. 
A death domain deleted version of this molecule was also created by using 
downstream PCR primers resulting in a CD4/IRAKC molecule which includes the IRAK 
residues 107-712. A similar death-domain deleted version of CD4/IRAK239 was created 
analogously and called CD4/IRAK239A. Included are IRAK residues 152-712. The 
constructs CD4/Toll (intracellular signaling domain of Toll fused to extracellular CD4), 
MyD88, TRAF6 and a dominant negative version of TRAF6, TRAF6C, all separately 
subcloned in pCINEO, were kindly provided by R. Medzhitov. 
3.2 Stable Cell Line 
A cell line consisting of the human embryonic kidney epithelial cells (293 cells) 
was stably transfected with a luciferase reporter system inducible by an NF-kB activated 
promoter. This cell line is referred to as 293Luc and was utilized to determine relative 




For each assay, appropriate quantities of DNA and the transfection reagent FuGene 6 
reagent (Boehrengier Manheim, Inc.) were used to transfect -2x10^ 293Luc cells in 2ml 
DMEM/10%FCS media in 35mm wells. The cells were allowed to grow overnight and 
were harvested, washed in 1ml PBS buffer and lysed with lysis buffer (Luciferase Assay 
Kit, Promega Corp.). An aliquot of 20 pi of lysate was then tested for luciferase activity 
with the addition of 100 pi luciferase substrate (Luciferase Assay Kit, Promega Corp.) 
and measured in a luminometer (Lumat LB 9501, Berthold Corp.). Results were 
standardized to a control transfection of vector (pClNEO) alone. 
3.4 Antibody 
All antibody used was IgG and was kindly provided by G. Losyev. 
4. Results 
4.1 NF-kB Activation 
Although IRAK has previously been shown to coimmunoprecipitate with IL-IRI in 
293 cells treated with IL-1 in a phosphorylation-dependent manner^^ it has never been 
shown to significantly induce NF-kB activation. To assess the ability of IRAK to drive 
NF-kB promoters, we transiently transfected 293 Luc cells with the chimeric molecule 
CD4/IRAK. As shown in Fig. 3, CD4/IRAK induced NF-kB activation in a dose- 
dependent fashion. 
To test whether or not kinase activity was necessary for IRAK to induce NF-kB, we 
transiently transfected 293 Luc cells with the CD4/IRAK239 kinase deficient construct. 
As with wild type, CD4/IRAK239 induced NF-kB in a dose-dependent fashion. 
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Activation was significantly less than that of wild type. Additionally, there was a plateau 
effect of NF-kB activation by CD4/IRAK239 at higher concentrations. 
NT-kB Acvdvation: CD4/IRAKvs. CD4/IRAK239 
Sample 
Fig. 3 Relative NF-kB Activation of CD4/IRAK constructs. Both CD4/IRAK contructs were transfected 
into 293 Luc cells. Both wild type and K239A did activated NF-kB in a dose-dependent fashion. NF-kB 
activation by CD4/1RAK239 was significantly less than that of wild type. Also, there was a blunting effect 
on NF-kB activation by CD4/IRAK239 at higher concentrations of transfected DNA. 
We also wanted to assess the ability of a dominant negative version of TRAF6, 
TRAF6C, to inhibit NF-kB activation by both wild-type and 239. Thus, either wild type 
or 239 DNA was cotransfected with TRAF6C into 293 Luc cells. The NF-kB activation 
of both was inhibited by TRAF6C. Fig. 4. 
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TRAF6C DNA (micrograms) 
Fig 4. Inhibition of NF-kB activation by TRAF6C. 293 Luc cells were transfected with 1.5 fig of either 
CD4/IRAK wild type or CD4/IRAK239. These cells were also transfected with TRAF6C, a dominant 
negative version of TRAF6, in various concentrations. Both CD4/IRAK and CD4/IRAK239 activated NF- 
kB as expected. Both were inhibited by TRAF6C in a relatively equivalent manner. 
Furthermore, we were interested in the nature of the interactions between proteins in 
the NF-kB pathway. In order to assess this, chimeric molecules containing the 
extracellular portion of CD4 and the IRAK protein with the death domain deleted were 
created. Both wild type death domain deleted (CD4/IRAKC) and K239A death domain 
deleted (CD4/IRAK239D) were constructed. Reasoning that the death domain is 
important for determining proper protein alignment via the MyD88 molecule we 
theorized that deletion of the death domain would result in lower activation. 
Additionally, assuming IRAK underwent autophosphorylation which would result from 
the close proximity of at least two IRAK proteins we attempted to induce NF-kB 
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activation by the death domain deleted molecules by cross-linking their extracellular CD4 
receptors with aCD4 IgG. Fig. 5. 
Both death domain deleted molecules activated NF-kB to a lesser extent than the full 
length proteins. Additionally, while cross-linking full-length CD4/IRAK with aCD4 IgG 
provided minimal additional activity over control cross-linking with aCD8 IgG, both 
CD4/IRAKC and CD4/IRAK239D activated NF-kB at a significantly higher level with 
aCD4. 
Effect of CD4 Cross-Linking on NT-kB Activation 
Sample 
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Fig, 5 Effect of cross-linking with aCD4 Ab on CD4/IRAK-induced NF-kB activation. 293 Luc cells 
were transfected with 2.0 of DNA. 18 hours later, all samples were cross-linked by either aCD4 or 
aCD8 Ab. 5 hours subsequently, cells were harvested and lysed. Lysates were measured for luciferase 
activity. There was no potentiation of NF-kB activation by aCD4 on full length CD4/IRAK molecules, 
either wild type or 239. There was an approximately 2-fold potentiation of NF-kB activation by aCD4 on 
death domain deleted CD4/IRAK molecules, both wild type and 239. Overall, there was less actvity in the 
death domain deleted molecules vs. the full length molecules. Cross-linking increased activation but it was 
still slightly less than that of full-length for both wild type and 239. 
Also of interest was the method by which Toll became activated which might reveal 
useful information regarding the nature of the Toll ligand. To address this question, we 
transfected 293 Luc cells with CD4/Toll and attempted to dimerize the receptors using 
aCD4 IgG. Fig. 6. The result was striking. CD4/Toll, as expected, induced NF-kB 
activation in the control aCD8 cross-linking. However, when we added a dimerizing 








CTRL CD4/ToO CD4/Toll 
Sample 
Fig. 6. NF-kB activation by CD4/Toll is induced by cross-linking the receptor with aCD4 IgG. 293 
Luc cells were transfected with 2.0 pg of CD4/Toll. 18 hours after transfection they were treated with 
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either aCD4 IgG or aCD8 IgG. Cells were then harvested 5 hours later and assayed for luciferase activity. 
The sample treated with aCD4 showed significantly more activity. 
4.2 AP.l activation 
In addition to the NF-kB pathway, Toll is known to signal through another 
transcription factor, AP.l. To assess whether IRAK is part of this signaling pathway we 
cotransfected 293 cells with an AP. 1 luciferase reporter gene and several proteins 
involved in ToU/NF-kB activation. Fig. 7. Both CD4/Toll and CD4/IRAK mildly 
activated AP.l while TRAF6 had a much more significant effect. 
AP-1 Activation 
Sample 
Fig. 7. Ap-1 Activation. 293 Luc cells were transfected with 2 pg of DNA. They were then harvested 24 
hours later and assayed for luciferase activity. Both CD4/Toll and CD4/IRAK moderately activated the 








Although there have been experiments that showed coimmunoprecipitation of IRAK 
with components of the IL-IR complex upon stimulation with IL-1 and that IRAK shares 
extensively homology with kinases involved in host defense of other organisms^^, there 
has not been a successful attempt to show significant NF-kB induction with IRAK. Here 
we show an almost 10-fold activation of NF-kB by our CD4/IRAK construct. Our data 
indicate that IRAK is indeed a SIIK involved in NF-kB signal transduction. 
Additionally, inhibition of IRAK-induced NF-kB activation by a dominant negative 
version of TRAF6 places IRAK upstream of TRAF6 in the pathway. Sequence analysis 
of IRAK reveals a death domain region which is homologous to a similar region on the 
adapter molecule MyD88 suggesting that MyD88 is the immediate upstream protein in 
the cascade. Experiments were also done showing that a dominant negative version of 
CO 
IRAK is capable of inhibiting MyD88-induced NF-kB activation. Thus, we conclude 
that IRAK is a serine/threonine innate immunity kinase involved in signal transduction of 
the NF-kB pathway. Additionally, IRAK is involved in the pathway between the proteins 
MyD88 and TRAF6. 
As shown, we were able to induce NF-kB activation with both CD4/IRAK wild type 
and CD4/IRAK239. This suggests that kinase activity is not absolutely necessary for 
IRAK fimction. Interestingly, this is similar to another known SIIK, receptor-interacting 
protein (RJP) which functions in the TNF receptor pathway. RIP possesses putative 
kinase domains but has been shown to induce NF-kB activity independent of the proper 
function of those domains.^'^ 
It is known that IRAK complexes with MyD88 upon activation of the upstream 
receptor prior to its phosphorylation.^^ That same study also showed that phosphorylation 
« 
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is likely a target for the degradation of IRAK via the proteasome. It seems likely then, 
that the kinase activity inherent in IRAK may represent a regulatory mechanism to 
prevent the overexpression of immunomodulatory peptides by the NF-kB pathway. 
Sepsis results from a massive increase in vascular permeability whose sequelae include 
high-output cardiac failure and end-organ perfusion insufficiencies. The initial insult, 
increased vascular permeability, is an evolutionarily adaptive response mediated by 
cytokines, predominantly TNF-a and IL-1.^^ This increased permeability is necessary to 
allow the effector cells and molecules of host defense access to the nidus of infection. 
When that system is overexpressed, sepsis results. The pathways of TNF-a and IL-1 
potentiation are mediated by similar SIIKs: RIP and IRAK, respectively. The data 
suggest that kinase activity is unnecessary for signal transduction for both of them yet 
that activity remains conserved over a billion years of evolution. Therefore, an adaptive 
function for this activity must exist. One model suggested by the data is that IRAK is 
recruited to the receptor complex independent of phosphorylation, transduces its signal to 
TRAF6 in an as yet undetermined manner, rapidly autophosphorylates and targets itself 
for destruction preventing overexpression of TNF-a and IL-1. If the signal is indeed 
independent of phosphorylation, as the data here suggests, simply dephosphorylating 
IRAK cannot turn off the signal. Therefore, degradation becomes the autoregulatory 
mechanism. 
Interestingly, the level of NF-kB activation induced by kinase deficient IRAK 
(CD4/IRAK239) lags behind that of wild type (CD4/IRAK). Additionally, the increase 
in NF-kB activation with an increase in amount of DNA transfected becomes blunted at 
higher levels of CD4/IRAK239. If we expect that kinase activity is required only for its 
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role in degradation and autoregulation we would suspect that kinase knockout molecules 
might potentiate NF-kB activation. Yet, this is not home out by the data. Almost 
counterintuitively, NF-kB activation decreases at higher concentrations of 
CD4/IRAK239. This suggests an as yet undiscovered function of IRAK kinase activity. 
This finding in the data is not inconsistent with the conclusion that IRAK functions as a 
homodimer that autophosphorylates. Perhaps only one of the two molecules in the dimer 
requires phosphorylation. At lower concentrations of CD4/IRAK239, endogenous wild 
type IRAK is recruited to the CD4/IRAK239 molecule forming a heterodimer wild 
type/K239A complex, phosphorylates itself or its partner protein and activates NF-kB. 
As the concentrations of K239A increase, fewer heterodimers are formed and more 
homodimer CD4/IRAK239 molecules spontaneously aggregate. Because neither one of 
the proteins in this complex possess kinase activity, the signal is disrupted and activation 
declines. 
There is additional evidence to suggest that IRAK does indeed function as a dimer. 
The experiment with the death domain deleted molecules provides some valuable insight. 
Because IRAK complexes with MyD88 via the death domain, deletion of the death 
domain would most likely remove the mechanism by which IRAK would aggregate 
should such a mechanism exist. That the death domain deleted mutants, both wild type 
and 239, were less effective in NF-kB induction is consistent with the notion that there is 
some protein superstructure that potentiates signal transduction and that superstructure is 
mediated through interactions involving the death domain. When we cross-linked the 
death domain deleted molecules, there was a significant increase in activation whereas 
the full length molecules saw little if any potentiation of signal. Because aCD4 IgG 
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would be expected to dimerize these molecules, it seems likely that the natural activated 
state of IRAK is a homodimer and that conclusion is suggested by our results from this 
experiment. 
Thus we are left with two seemingly incongruent conclusions. On the one hand we 
have activation by kinase deficient molecules, which is consistent with at least one other 
SIIK. On the other hand we have a lower level of activation versus wild type and 
declining activation with increased concentration of CD4/IRAK239. This suggests the 
possibility that kinase activity may be important for signal transduction purposes. As we 
have stated before, the closest mammalian homologue of IRAK is human mixed lineage 
kinase which itself is more closely related to tyrosine kinases than serine/threonine 
kinases. Additionally, IRAK shares more homology with SIlKs in invertebrates and 
plants than it does with other mammalian kinases.^^ This suggests that the SIIKs are a 
semi-distinct class of kinases that evolved very early on. As such, one might expect 
unique structural and functional features associated with this class of proteins. The 
degradation of IRAK might be one such feature. Most kinases can rapidly undergo 
dephosphorylation by phosphatase molecules that results in inactivation. There has been 
no evidence to suggest such a mechanism exists for IRAK. Indeed, it seems that the only 
mechanism for the inactivation of IRAK is its phosphorylation-dependent degradation. 
One possible explanation for our seemingly contradictory evidence is that kinase 
activity in IRAK and perhaps in all SIIKs has a dual role. It has a well established 
function in degradation with autoregulatory implications and may well have a role in 
signal transduction also. Although there is no known substrate for IRAK kinase activity 






















































































autophosphorylates or cross-phosphorylates when dimerized which might induce 
conformational changes and allow the binding of TRAF6 or other downstream molecules. 
This is consistent with our data that shows mild activation by CD4/IRAK239 that 
decreases at high concentrations. While we would expect that activation should be 
markedly decreased by the failure of IRAK239 to phosphorylate itself to induce this 
assumed binding event there is a counterbalance effect by the mutation’s ability to inhibit 
degradation and the ability of CD4/IRAK239 to recruit wild type IRAK into a protein 
dimer. Presumably, one molecule of wild type IRAK in a dimer would retain some 
ability to activate. As we raise the concentration of kinase deficient IRAK we increase 
the probability that the IRAK dimers will now consist of two molecules of 
CD4/IRAK239 which, without any kinase activity, would terminate signal transduction 
and result in a decrease in NF-kB activation. 
The question of why this system of degradation-for-deactivation evolved still remains 
unanswered. Presumably, IRAK, when phosphorylated, can bind downstream molecules 
including TRAF6 and others which remain unknown at present. Perhaps the formation of 
this complex is very energetic and simply dephosphorylating IRAK does not provide 
enough instability to cause spontaneous disruption. Perhaps the answer is simply that the 
SIIKs evolved prior to the evolution of phosphatases and never faced selective pressure 
to adapt. Nevertheless, the search for downstream molecules and their interaction with 




Although there is reeent data that implicates LPS in the activation of the mammalian 
Toll receptor , the search for the ligand remains active. We know that the ligand for 
Drosophila Toll is spatzle, which itself is generated by an endogenous proteolytic 
reaction. Thus, the possibility exists that the ligand for mammalian Toll is an 
endogenous signal. 
In order to gain some insight into the function of Toll we transiently transfected 293 
Luc cells with a chimeric molecule consisting of the extracellular portion of CD4 and the 
signaling domain of Toll. After cross-linking with aCD4 IgG, NF-kB activation was 
potentiated by a factor of two. This suggests that Toll functions in a dimer, binding one 
molecule of MyD88. In this model, the TIR domain trimerizes, two domains fi-om the 
intracelluar portion of Toll and one from the MyD88 protein. The implication is that the 
ligand for Toll may have two identical epitopes capable of binding the same region on 
two Toll molecules. Fig. 8 
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Fig. A schematic representation of the organization of the To11/NF-kB pathway. The data is consistent 
with a potentiation of NF-kB activation when Toll is dimerized. In such a complex, one MyD88 molecule 
would then associate with the dimerized Toll complex forming a TIR domain trimer. Then a death domain 
trimer would link the one MyD88 molecule with two molecules of IRAK. Again, the data from the death 
domain deleted experiments is consistent with potentiation of NF-kB activation by IRAK dimerization. 
The IRAK dimer then autophosphorylates or cross-phosphorylates which is likely to have a dual role: 1) it 
signals for the degradation of IRAK by the proteasome and 2) it induces a conformational change which 
allows IRAK to transduce the activation signal to downstream molecules. The end result is the 
phosphorylation of IkB and the translocation of NF-kB to the nucleus where it induces the transcription of 
immune response genes. 
Implicit in the assumption that the ligand possesses two identical epitopes is the high 
probability that such a ligand would be endogenous. The model for such a receptor and 
ligand is the receptor for platelet-derived growth factor (PDGF).^^ The PDGF receptor is 
a receptor tyrosine kinase capable of autophosphorylation when it becomes dimerized. 








binding epitopes with a regular structure. This is true for any receptor that forms dimers. 
This ligand is likely itself to be the product of an endogenous process. LPS does not 
possess such symmetry and our data would be inconsistent with an assertion that LPS is 
the ligand for Toll. Nevertheless, there is evidence that suggests LPS is involved in Toll 
activation. It is likely that there exists an intermediate step between initial recognition 
of LPS and activation of Toll and that this step generates the ligand for the Toll receptor. 
Although it may appear that activation in the absence of cross-linking the Toll 
receptor is higher than that which would be predicted by our model, it is likely this is the 
result of experimental design. By transfecting large quantities of CD4/TolI, the TIR 
domain becomes overexpressed. In such a state, the rate of spontaneous dimerization of 
the CD4/Toll molecule increases. Thus, as is consistent with the data, activation will 
increase despite the fact that we have designed no specific mechanism for receptor 
dimerization. 
5.3 AP-1 
Interestingly, the AP-1 pathway has been shown to become activated by the Toll 
receptor but remain quiescent with IL-IR activation. Because these two receptors share 
an NF-kB activation pathway, it was interesting to discover that components of this 
pathway can mildly (Toll, IRAK) and significantly (TRAF6) activate AP-1. This 
suggests an alternative signaling mechanism by which the AP-1 pathway distinguishes 
between Toll and IL-IR activation. The data is consistent with the notion that this 
discrimination does not occur at the level of IRAK or TRAF6 as both can induce 
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6. Conclusions 
The link between innate and adaptive immunity has been avidly pursued for several 
years. Because of its central role in the induction of host defense responses, the NF-kB 
pathway has occupied much of that attention. Many questions regarding the function of 
the NF-kB pathway and its constituent proteins have been answered. Nevertheless, many 
questions remain. 
One area that bears further study is the function of IRAK. Specifically, what is the 
role of kinase activity in signal transduction? We have shown here that kinase activity is 
not strictly necessary for NF-kB activation yet we also have data that suggests it may 
play a part. Does IRAK complex with downstream molecules in a phosphorylation- 
dependent process? Is there an intermediate molecule between IRAK and TRAF6 
involved in this putative protein complex? Is the function of IRAK unique or is it shared 
by other SIIKs, implying that this is a novel class of proteins with properties not shared 
by other kinases? 
Of significant importance is the elucidation of the mechanism of induction of 
costimulation. Is the NF-kB pathway uniquely responsible for inducing costimulation? 
Studies examining the role of each of the constituent molecules of NF-kB in induction of 
costimulation would be very useful as would experiments designed to elucidate other 
pathways/receptors with the ability to initiate an adaptive immune response. 
The implications for these types of studies are far-reaching. As we develop our 
understanding of how innate and adaptive immunity are linked, either through NF-kB or 

other mechanisms, our understanding of an enormous variety of pathological states 
increases. Additionally, the potential to treat these disease processes also grows. 
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One area that has attracted much attention is the manipulation of host defense 
elements for the treatment of cancer. Specifically, there have been efforts to develop a 
dendritic cell vaccination for melanoma. Malignant melanoma seems an ideal target for 
vaccination because its cells expresses an array of unique antigens, including the MAGE 
(for melanoma antigen) proteins first describe in association with melanoma in 1991. 
As our understanding about the role and induction of B7.1 and B7.2 in the initiation of an 
adaptive immune response grows, perhaps we will be able to manipulate it to maximize a 
host defense response against these MAGE proteins or other self-peptides expressed only 
on malignant cells. 
Conversely, the spectrum autoimmune disease poses a different problem. A single 
feature links these diseases. All are manifestations of an immune response that has 
become activated against self-antigens. Many of these diseases remain a mystery as to 
their etiology. Some have clear associations with a previous infection, i.e. 
poststreptococcal glomerulonephritis. Some, including multiple sclerosis, which is the 
result of a host defense response directed against the myelin-producing schwann cells of 
the nervous system, are less well understood. Perhaps future study into the function of 
NF-kB and the induction of costimulation can provide not only insight into the etiology 
of autoimmunity but also a method to develop host tolerance for self-peptides. 
In addition to these examples and that of sepsis highlighted earlier, the understanding 
of host defense has remarkable implications in a wide variety of other fields. Perhaps one 
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day, the manipulation of our own immune systems will be a therapy as commonplace as 
the prescription of antibiotics. 
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